This review will summarize the current trends in the diagnosis and management of DCIS and will highlight ongoing trials that are shaping future management of this entity.
E. Shelley Hwang, MD, MPH
The DCIS Score provides clinically relevant information about personal risk that can guide patient discussions and facilitate shared decision making.
Breast cancers of lobular histology are not frequently encountered, but are nevertheless the second most common histologic subtype of breast cancer after ductal adenocarcinoma.
In this review of hepatic resection
for metastatic breast cancer, the
authors argue that a small group
of women with isolated liver metastases
may be appropriate candidates for
surgical resection. Although some data
have been reported, the few published
studies represent small, retrospective
single-institutional series with no standardized
criteria for resection. Nevertheless,
the potential prospect of
improved patient outcome in the setting
of liver metastases from breast
cancer deserves further consideration.
Lymphedema continues to plague women after breast cancer treatment. The cosmetic deformity cannot be disguised with normal clothing; physical discomfort and disability are associated with the enlargement; and recurrent episodes of cellulitis and lymphangitis may be expected. Added to the physical symptoms is the distress caused unintentionally by clinicians, who are more interested in cancer recurrence and often trivialize the nonlethal nature of lymphedema.